Emily Leproust Sells 41,570 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 41,570 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $151.98, for a total transaction of $6,317,808.60. Following the completion of the transaction, the chief executive officer owned 770,729 shares in the company, valued at approximately $117,135,393.42. This trade represents a 5.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Stock Performance

TWST stock traded up $3.10 during mid-day trading on Thursday, hitting $153.16. 1,251,874 shares of the company were exchanged, compared to its average volume of 1,533,463. The business has a 50 day simple moving average of $104.57 and a 200-day simple moving average of $72.62. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $9.60 billion, a PE ratio of -68.99 and a beta of 2.14. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $155.44.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The firm had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. Twist Bioscience’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.33 EPS. On average, equities analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on TWST shares. Guggenheim reaffirmed a “buy” rating on shares of Twist Bioscience in a report on Monday. Leerink Partners set a $110.00 target price on shares of Twist Bioscience in a research report on Thursday, July 16th. Barclays raised their price target on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Finally, UBS Group set a $89.00 target price on shares of Twist Bioscience in a report on Monday, June 15th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.30.

Institutional Investors Weigh In On Twist Bioscience

Large investors have recently bought and sold shares of the company. Quarry LP bought a new position in Twist Bioscience in the 3rd quarter valued at about $28,000. Western Wealth Management LLC bought a new stake in shares of Twist Bioscience during the 1st quarter worth approximately $31,000. Strs Ohio acquired a new stake in shares of Twist Bioscience during the 1st quarter worth approximately $33,000. Strategic Advocates LLC boosted its position in shares of Twist Bioscience by 562.7% during the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after acquiring an additional 906 shares in the last quarter. Finally, SBI Securities Co. Ltd. increased its stake in Twist Bioscience by 68.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock valued at $44,000 after acquiring an additional 571 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.